Dashboard
Manage Tickers

SGHTSight Sciences, Inc.

Nasdaq sightsciences.com


$ 5.47 $ -0.03 (-0.54 %)    

Tuesday, 06-Aug-2024 15:59:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 448.13 $ 2.55 (0.57 %)
DIA $ 393.25 $ 0.73 (0.19 %)
SPY $ 529.95 $ 2.16 (0.41 %)
TLT $ 96.11 $ 0.07 (0.07 %)
GLD $ 221.80 $ -0.21 (-0.09 %)
$ 5.49
$ 5.47 x 100
$ 10.00 x 655
-- - --
$ 1.04 - $ 9.03
172,164
na
273.97M
$ 2.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-02-2024 06-30-2024 10-Q
2 05-06-2024 03-31-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 03-16-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-11-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-24-2022 12-31-2021 10-K
12 11-10-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-hold-on-sight-sciences
Needham Reiterates Hold on Sight Sciences
08/02/2024 09:31:37

Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) with a Hold.

sight-sciences-narrows-fy24-revenue-guidance-from-81m---85m-to-81m---83m-est-83832m
Sight Sciences Narrows FY24 Revenue Guidan...
08/01/2024 21:12:54

The Company expects dry eye revenue for full year 2024 to be less than $3.0 million, including the $2.1 million of revenue achi...

sight-sciences-continues-to-expect-double-digit-surgical-glaucoma-revenue-growth-in-h2
Sight Sciences Continues To Expect Double-...
08/01/2024 21:10:11

However, the Company expects Dry Eye revenue to decrease as it implements an increase in dry eye pricing effective October 1, 2...

sight-sciences-q2-2024-gaap-eps-025-beats-030-estimate-sales-21370m-beat-21347m-estimate
Sight Sciences Q2 2024 GAAP EPS $(0.25) Be...
08/01/2024 20:37:58

Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30...

morgan-stanley-maintains-equal-weight-on-sight-sciences-raises-price-target-to-65
Morgan Stanley Maintains Equal-Weight on S...
07/15/2024 17:10:11

Morgan Stanley analyst Cecilia Furlong maintains Sight Sciences (NASDAQ:SGHT) with a Equal-Weight and raises the price targe...

citigroup-maintains-neutral-on-sight-sciences-raises-price-target-to-65
Citigroup Maintains Neutral on Sight Scien...
07/11/2024 01:18:51

Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $6 t...

sight-sciences-announces-publication-of-twelve-month-results-of-sahara-rct-data-demonstrating-improved-signs-and-symptoms-of-dry-eye-disease-for-tearcare-patients-crossed-over-ffom-restasis
Sight Sciences Announces Publication Of Tw...
05/28/2024 20:11:31

sight-sciences-announces-the-results-as-published-in-the-journal-clinical-ophthalmology-of-a-new-analysis-of-the-romeo-study-data-findings-suggest-that-ab-interno-canaloplasty-coupled-with-trabeculotomy-using-omni-was-as-effective-at-lowering-iop-and-reducing-medication-usage-in-advanced-glaucoma-patients-as-it-was-in-mild-and-moderate-glaucoma-patients
Sight Sciences Announces The Results As Pu...
05/28/2024 12:32:24

piper-sandler-reiterates-neutral-on-sight-sciences-raises-price-target-to-6
Piper Sandler Reiterates Neutral on Sight ...
05/03/2024 13:40:29

Piper Sandler analyst Matt O'Brien reiterates Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target fr...

needham-reiterates-hold-on-sight-sciences
Needham Reiterates Hold on Sight Sciences
05/03/2024 09:55:10

Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) with a Hold.

sight-sciences-reaffirms-fy24-revenue-guidance-81m-85m-vs-8248m-est
Sight Sciences Reaffirms FY24 Revenue Guid...
05/02/2024 21:56:52

sight-sciences-q1-2024-gaap-eps-033-misses-030-estimate-sales-19265m-beat-18382m-estimate
Sight Sciences Q1 2024 GAAP EPS $(0.33) Mi...
05/02/2024 21:23:37

Sight Sciences (NASDAQ:SGHT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0....

sight-sciences-announces-34m-patent-infringement-verdict-against-alcon-and-its-hydrus-microstent-for-microinvasive-glaucoma-surgery--monetary-damages-comprised-of-55m-in-lost-profits-and-285m-in-royalty-damages-for-sales-of-the-hydrus-microstent-for-the-period-from-its-commercial-launch-through-trial
Sight Sciences Announces $34M Patent Infri...
04/29/2024 12:06:24

sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-the-aqueous-outflow-restorative-procedure-with-omni-surgical-system-technology-is-effective-at-lowering-both-iop-and-iop-reducing-medications-at-2-years-in-patients-with-glaucoma
Sight Sciences Announces The Publication O...
04/10/2024 20:08:14

Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused o...

needham-reiterates-hold-on-sight-sciences
Needham Reiterates Hold on Sight Sciences
04/10/2024 09:24:18

Needham analyst David Saxon reiterates Sight Sciences (NASDAQ:SGHT) with a Hold.

sight-sciences-shares-are-trading-higher-after-the-company-announced-data-from-studies-of-two-of-its-glaucoma-and-dry-eye-technologies-will-be-presented-at-the-2024-american-society-of-cataract-and-refractive-surgery-annual-meeting
Sight Sciences shares are trading higher a...
04/03/2024 11:26:08

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
04/02/2024 20:31:04

sight-sciences-announces-the-results-of-the-3-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct-at-the-2024-american-society-of-cataract-and-refractive-surgery-annual-meeting
Sight Sciences Announces The Results Of Th...
04/02/2024 20:13:05

Clinical results demonstrate long-term efficacy of the OMNI® Surgical System for primary open-angle glaucoma and support use of...

stifel-maintains-buy-on-sight-sciences-raises-price-target-to-7
Stifel Maintains Buy on Sight Sciences, Ra...
03/08/2024 15:47:44

Stifel analyst Thomas Stephan maintains Sight Sciences (NASDAQ:SGHT) with a Buy and raises the price target from $6 to $7.

sight-sciences-projects-2024-revenue-81m-85m-vs-8241m-est
Sight Sciences Projects 2024 Revenue $81M-...
03/07/2024 22:11:09

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION